相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
Robert Puckrin et al.
HAEMATOLOGICA (2021)
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
Ing S. Tiong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation
Alexandros Spyridonidis
BLOOD (2020)
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Richard Dillon et al.
BLOOD (2020)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The clinical mutatome of core binding factor leukemia
Sabrina Opatz et al.
LEUKEMIA (2020)
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Seth E. Karol et al.
LANCET ONCOLOGY (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Sibylle Cocciardi et al.
NATURE COMMUNICATIONS (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G. Ruecker et al.
BLOOD (2019)
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Linus Angenendt et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT
Julian Borrow et al.
BLOOD (2019)
Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapseafter allogeneic haematopoietic cell transplantation inadults with inv(16) acute myeloid leukaemia
Fei-Fei Tang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Targeted Next-Generation Sequencing for Detecting MLL Gene Fusions in Leukemia
Sadia Afrin et al.
MOLECULAR CANCER RESEARCH (2018)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
Raphael Itzykson et al.
BLOOD (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Time to repeal and replace response criteria for acute myeloid leukemia?
Clara Derber Bloomfield et al.
BLOOD REVIEWS (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
A. K. Burnett et al.
LEUKEMIA (2018)
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
Ann-Kathrin Eisfeld et al.
LEUKEMIA (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia
Hidemasa Matsuo et al.
PEDIATRICS INTERNATIONAL (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Minimal residual disease in acute myelogenous leukemia
N. M. Cruz et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
Ya-Zhen Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT
Jonathan Canaani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade et al.
BLOOD (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
Anthony D. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation
Carmen Di Grazia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Nicolas Duployez et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Genomic Classification in Acute Myeloid Leukemia
Francois Lemonnier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia
Sai Huang et al.
MEDICAL SCIENCE MONITOR (2016)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Prognostic Significance of NPM1 Mutations in the Absence of FLT3-Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
Fabiana Ostronoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
Anna K. Andersson et al.
NATURE GENETICS (2015)
DLI after haploidentical BMT with post-transplant CY
A. Ghiso et al.
BONE MARROW TRANSPLANTATION (2015)
An Efficient Method for Identifying Gene Fusions by Targeted RNA Sequencing from Fresh Frozen and FFPE Samples
Jonathan A. Scolnick et al.
PLOS ONE (2015)
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
Sylvain Pilorge et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia-Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Jing Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital et al.
BLOOD (2014)
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
Fabiana Ostronoff et al.
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
Yu Wang et al.
BLOOD (2014)
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Marta Pratcorona et al.
BLOOD (2013)
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
Jochen Greiner et al.
BLOOD (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu et al.
BLOOD (2013)
A novel RT-qPCR assay for quantification of theMLL-MLLT3fusion transcript in acute myeloid leukaemia
Lotte Abildgaard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
NUP98-NSD1 Fusion in Association with FLT3-ITD Mutation Identifies a Prognostically Relevant Subgroup of Pediatric Acute Myeloid Leukemia Patients Suitable for Monitoring by Real Time Quantitative PCR
Susanna Akiki et al.
GENES CHROMOSOMES & CANCER (2013)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Donor Lymphocyte Infusion Induces Polyspecific CD8+ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With NPM1 Mutation
Susanne Hofmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene
A. Fasan et al.
LEUKEMIA (2013)
Analysis of NUP98/NSD1 translocations in adult AML and MDS patients
F. Thol et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia
Tanja A. Gruber et al.
CANCER CELL (2012)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Jan J. Cornelissen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology
B. Glimelius et al.
ANNALS OF ONCOLOGY (2011)
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Brunangelo Falini et al.
BLOOD (2011)
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern
Iris H. I. M. Hollink et al.
BLOOD (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia
B. V. Balgobind et al.
LEUKEMIA (2011)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
Susanne Schnittger et al.
BLOOD (2009)
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
Brian V. Balgobind et al.
BLOOD (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Cryptic MLL-AF10 fusion caused by insertion of duplicated 5′ part of MLL into 10p12 in acute leukemia:: a case report
M Jarosova et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia
PD Kottaridis et al.
LEUKEMIA & LYMPHOMA (2003)
Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia
C Scholl et al.
GENES CHROMOSOMES & CANCER (2003)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction
G Mitterbauer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
